Twist Bioscience Corp TWST
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
3/9
Piotroski F — financial health
-2.72
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $376.6M | -$77.7M | — | -$75.6M | $473.0M |
| 2024 | $313.0M | -$208.7M | — | -$69.2M | $472.7M |
| 2023 | $245.1M | -$204.6M | — | -$170.3M | $623.4M |
| 2022 | $203.6M | -$217.9M | — | -$226.2M | $789.4M |
| 2021 | $132.3M | -$152.1M | — | -$139.3M | $580.8M |
| 2020 | $90.1M | -$139.9M | — | -$152.1M | $336.3M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.72 (distress)
- Working capital / assets 0.376
- Retained earnings / assets -2.056
- EBIT / assets -0.212
- Equity / liabilities 2.8
Source: SEC EDGAR filings · CIK 0001581280 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.